Segra is at the forefront of agricultural technology, spearheading a revolution in the cannabis industry. The company's focus on Plant Tissue Culture (PTC) has led to the development of superior cannabis plantlets, empowering growers with efficient and high-yielding cultivation methods. This article delves into Segra's groundbreaking innovations, including its industry-leading cannabis pathogen detection and DNA fingerprinting tests. We will also explore Segra's exclusive partnerships, its role in preserving and supplying top-tier genetics, and the advantages it offers to cannabis cultivators worldwide.
Segra's success lies in its mastery of Plant Tissue Culture, a four-stage process (initiation, multiplication, rooting, and acclimation) that results in true-to-type plantlets free from detectable pathogens and inter- and intracellular bacteria and fungi. Segra's Stage III Plantlets, introduced in 2020, are now available in various formats for domestic and international shipping. Compared to conventional vegetative propagation, these laboratory-produced plantlets offer superior control over pathogens, crop uniformity and consistency over time.
Segra's DNA fingerprinting test is a game-changer for cannabis farmers, regulators, and breeders alike. This low-cost, high-throughput solution allows for the verification of cultivar genetic identity, streamlining supply chain management. Moreover, it enables breeders to make well-informed decisions by pre-screening large volumes of genotypes for optimal phylogenetic grouping.
In a major milestone, Segra has formed exclusive global distribution agreements with renowned cannabis breeders and collectors, such as Grounded Genetics and The Holding Company. This collaboration brings a remarkable collection of award-winning genetics to Canadian and international markets. Custom phenotype selection and breeding projects are also on offer, providing growers with a dedicated program of cultivar development for optimal results in their environment.
Securing its position as an industry leader, Segra obtained Health Canada's Analytical Testing License in 2023. Segra’s Molecular Lab now offers pathogen testing, Hop Latent Viroid (HLVd) and DNA fingerprinting for licensed cannabis producers. This in-house molecular lab also sets Segra apart from other tissue culture nurseries, by guaranteeing pathogen-tested, true-to-type, and high-quality plantlets for customers.
Segra's partnership with Compound Genetics has allowed Canadian and international growers access to an array of cutting-edge cultivars personally selected by the team at Compound Genetics. Through Segra's tissue culture nursery, these exclusive genetics are available to cultivators as Segra’s pathogen-tested, true-to-type, tissue culture plantlets, ensuring high-quality plantlets consistent delivery of high-quality plants.
Recognized as the Best Genetics Provider at the Grow Up Awards, Segra maintains a strong and diverse portfolio of commercially tested cannabis cultivars. With a focus on clean genetics, Segra's state-of-the-art molecular biology lab ensures the highest standards of testing, DNA fingerprinting, and pathogen mitigation.
Segra's Satellite Lab program has seen tremendous success, including a partnership with a top California greenhouse producer. By providing expert lab design and management services, Segra facilitates the production of high-value cultivars at large-scale facilities, addressing the challenges of pathogen management and consistent crop output over time.
As a leading Canadian Cannabis nursery, Segra's pioneering work in Plant Tissue Culture and DNA fingerprinting has transformed the cannabis industry. Through strategic partnerships, cutting-edge lab services, and a commitment to top quality genetics, Segra empowers growers worldwide to cultivate better plants with greater efficiency and reliability. As the cannabis industry continues to evolve, Segra remains a trailblazer in ag-tech, driving innovation and progress in this dynamic field.